Joshua C. Rosen
YOU?
Author Swipe
View article: Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms Open
Our findings confirm AZD4625 as a highly active KRASG12C inhibitor. This data also supports the use of PDX models in understanding resistance mechanisms that may be leveraged to develop more active combination therapies.
View article: Supplementary Data Table S1, 3-4 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Supplementary Data Table S1, 3-4 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer Open
Supplementary Data Table S1, 3-4
View article: Data from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Data from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer Open
Purpose:Non–small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide. There is an unmet need to develop novel clinically relevant models of NSCLC to accelerate identification of drug targets and our unders…
View article: Data from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Data from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer Open
Purpose:Non–small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide. There is an unmet need to develop novel clinically relevant models of NSCLC to accelerate identification of drug targets and our unders…
View article: Supplementary Data Figure S1-5, Table S2, 5-7 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Supplementary Data Figure S1-5, Table S2, 5-7 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer Open
Supplementary Data Figure S1-5, Table S2, 5-7
View article: Supplementary Data Figure S1-5, Table S2, 5-7 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Supplementary Data Figure S1-5, Table S2, 5-7 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer Open
Supplementary Data Figure S1-5, Table S2, 5-7
View article: Supplementary Data Table S1, 3-4 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Supplementary Data Table S1, 3-4 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer Open
Supplementary Data Table S1, 3-4
View article: Direct GDP-KRAS<sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg
Direct GDP-KRAS<sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg Open
Kirsten rat sarcoma viral oncogene homolog mutations are observed in 25% of lung adenocarcinoma and 40% of these are G12C mutations. Historically, no approved targeted agents were available for patients with any KRAS mutation, and response…
View article: Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts Open